
Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome
TAN Xiu-Zhen, WU Shi-Guang, ZHANG Jian-Hua, LI Xiao-Fen, GAO Ping-Ming, WANG Yu
Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (12) : 1237-1241.
Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome
Objective To study the clinical efficacy of porcine pulmonary surfactant (PS) combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome (MAS). Methods Seventy neonates with MAS were enrolled for a prospective study. The neonates were randomly assigned to PS alone treatment group and PS+budesonide treatment group (n=35 each). The PS alone treatment group was given PS (100 mg/kg) by intratracheal instillation. The treatment group was given budesonide suspension (0.25 mg/kg) combined with PS (100 mg/kg). Results The rate of repeated use of PS in the PS+ budesonide group was significantly lower than that in the PS alone group 12 hours after treatment (P < 0.05). The improvement of PaO2/FiO2, TcSaO2, PaO2, and PaCO2 in the PS+ budesonide group was significantly greater than that in the PS alone group 6, 12, and 24 hours after treatment (P < 0.05). The chest X-ray examination showed that the pulmonary inflammation absorption in the PS+ budesonide group was significantly better than that in the PS alone group 48 hours after treatment (P < 0.05). The incidence of complications in the PS+budesonide group was significantly lower than that in the PS alone group (P < 0.05), and the average hospitalization duration was significantly shorter than that in the PS alone group (P < 0.01). Conclusions PS combined with budesonide suspension intratracheal instillation for the treatment of neonatal MAS is effective and superior to PS alone treatment.
Pulmonary surfactant / Budesonide suspension / Meconium aspiration syndrome / Neonate
[1] 马海燕, 刘翠青. 胎粪吸入综合征治疗研究进展[J]. 中国新生儿科杂志, 2009, 24(1):57-59.
[2] 董克江, 李娜, 周海燕, 等. 新生兔胎粪吸入后生理参数的观察[J]. 医学综述, 2010, 16(21):3359-3360.
[3] 夏耀方, 刘翠青. 外源性肺泡表面活性物质对胎粪吸入综合征患儿肺功能及血管内皮生长因子的影响[J]. 中国实用儿科杂志, 2013, 28(1):31-34.
[4] 杨彤, 沈琪, 黄献文. 肺表面活性物质治疗新生儿胎粪吸入综合征的系统评价[J]. 中国实用儿科杂志,2010, 25(3):220-226.
[5] 潘家华. 新生儿胎粪吸入综合征的诊治进展[J]. 临床儿科杂志,2008, 26(9):823-826.
[6] 王六超, 农绍汉. 新生儿胎粪吸入综合征的治疗进展[J].医学综述, 2014, 20(22):4160-4162.
[7] 罗菲菲, 杨迪元, 陈攀, 等. 肺表面活性物质治疗新生儿胎粪吸入综合征临床疗效的meta分析[J]. 中国当代儿科杂志, 2012, 14(6):413-417.
[8] 李云, 武荣. 布地奈德雾化吸入治疗新生儿胎粪吸入综合征的临床观察[J]. 中华全科医学, 2013, 11(5):727-728.
[9] 罗思华, 唐渊, 梁创, 等. 普米克令舒联合硫酸镁治疗新生儿胎粪吸入综合征的临床研究[J]. 中国医药导报, 2015, 12(14):125-128.
[10] 杜立中. 吸入综合征[M]//邵肖梅, 叶鸿瑁, 邱小汕. 实用新生儿学. 第4版. 北京:人民卫生出版社, 2011:398-401.
[11] 马晓路, 李如意,译. ACoRN教程[M]//ACoRN编委会. 重危新生儿的急症监护. 杭州:浙江大学出版社, 2009:1-21.
[12] 林新祝, 赖基栋, 兰朝阳, 等. 猪肺表面活性物质气管内灌洗治疗重症新生儿胎粪吸入综合征的临床研究[J]. 中国当代儿科杂志, 2014, 16(7):709-713.
[13] 杨迪元, 华子瑜. 糖皮质激素治疗胎粪吸入综合征的研究进展[J]. 中国当代儿科杂志, 2010, 12(6):505-508.
[14] Mokra D, Drgova A, Kopincova J, et al. Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury[J]. Adv Exp Med Biol, 2013, 756:189-196.
[15] 杨迪元, 沈莉荣, 于爱真, 等. 糖皮质激素治疗胎粪吸入综合征疗效和安全性的meta分析[J]. 中国循证儿科杂志, 2011, 6(2):126-134.
[16] Liu YJ, Soumelis V, Watanabe N, et al. TSLP:an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation[J]. Annu Rev Immunol, 2007, 25:193-219.
[17] 陈真, 杜强, 周林福, 等. 布地奈德对A549细胞胸腺基质淋巴细胞生成素表达作用的研究[J]. 现代医学生物进展, 2009, 9(10):1820-1823.
[18] Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis:a randomised, double blind, placebo controlled study[J]. Gut, 2005, 54(7):960-965.
[19] Driban JB, Barr AE, Amin M, et al. Joint inflammation and early degeneration induced by high-force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder[J]. J Biomed Biotechnol, 2011, 2011:691412.
[20] 吴君华, 柳晨, 裴元英. 布地奈德剂型的研究进展及其临床应用[J]. 中国临床药学杂志, 2007, 16(1):59-62.